The research investigated, for the first time, the efficacy of two different types of anti-inflammatories on patients with severe forms of COVID-19: the interleukin IL-1 inhibitor, called Anakinra, and the IL-6 inhibitors Tocilizumab and Sarilumab. Here, IL6 is linked to COVID-19.